Evidence map›Paper›PMID 21898040›Full record

Trial reportInternational urology and nephrology2012

Efficacy of pentoxifylline in prevention of contrast-induced nephropathy in angioplasty patients.

Ata Firouzi, Ali Eshraghi, Farshad Shakerian, Hamid Reza Sanati, Negar Salehi, Ali Zahedmehr, Reza Kiani, Mohsen Madani, Ali Pedarzadeh

Abstract readComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International urology and nephrology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Ata FirouziDepartment of Cardiology, Shahid Rajaie Cardiovascular Medical and Research Hospital, P. O. Box: 13185-1678 Tehran, Iran.
Ali Eshraghi
Farshad Shakerian
Hamid Reza Sanati
Negar Salehi
Ali Zahedmehr
Reza Kiani
Mohsen Madani
Ali Pedarzadeh
Shaheed Rajaei Cardiovascular Medical and Research Center · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundContrast-induced nephropathy (CIN) is an adverse consequence of contrast media use that results in significant morbidity and mortality and adds significant costs to diagnostic and interventional cardiology procedures. Various pathophysiological mechanisms have been proposed for CIN and various agents have been tested for its prevention. There is currently a general agreement that adequate pre-procedure hydration constitutes the cornerstone of prevention, yet there are reports of the use of some other agents with various efficacies. We prospectively tested pentoxifylline (PTX), an antioxidant, anti-inflammatory drug, for CIN prevention in patients undergoing coronary angioplasty. MATERIALS AND

methodsIn this prospective, randomized, single-blind, single-center clinical trial, 286 consecutive patients were randomly assigned to the control group (n = 146), with routine treatment and no PTX, or the study group (n = 140), with routine treatment and PTX, 400 mg/tid from 24 h before to 24 h after coronary angioplasty. Serum creatinine was measured before and 2 days after the procedure. The primary end point was the occurrence of CIN within 48 h.

resultsThe control and PTX groups were comparable in the overall predicted risk of CIN. Also, the type and volume of the contrast agent were not significantly different between the two groups. Following angioplasty, CIN occurred in 20 (13.69%) patients in the control group and in 12 (8.5%) patients in the study group; the difference was not statistically significant (P = 0.17). Additionally, there was no mortality and need for hemodialysis in either group.

conclusionIn angioplasty patients, the prophylactic oral use of PTX could be recommended for CIN prevention, although no statistically significant protective effect was documented.

Indexed as

Acute Kidney InjuryAdultAngioplasty, Balloon, CoronaryContrast MediaCoronary AngiographyCoronary Artery DiseaseDose-Response Relationship, DrugFemaleFollow-Up StudiesFree Radical ScavengersHumansInjections, IntravenousMaleMiddle AgedPentoxifyllineProspective StudiesContrast MediaFree Radical ScavengersPentoxifylline

Identifiers

PMID21898040
OpenAlexW1972883604

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.